Longevity Clinics in Europe

Every public health system in Europe runs a short list of screening programmes for healthy adults and then deliberately declines to go further, and the private clinics listed across this region sell into exactly that gap. Two quite different businesses do it. The residential model sells a stay of several days or a week at a clinic-hotel in the Alps, on the Mediterranean or in an old spa town, with imaging, blood work, consultations, meals and the room inside a single price; the urban diagnostic model sells the appointment itself, a scanner slot and a doctor's hour booked singly in a city centre, often alongside a radiology practice or a private hospital.

What separates two listings offering the same named tests is rarely the test. It is who reads the result and on which national register that person sits, whether the scan or panel has an ordinary route through the public system when there is a clinical reason for it, and what is supposed to happen in the six months afterwards. Those things vary sharply by country, because private practice sits differently beside the public system in each one and because the rules on prescribing a medicine outside its licensed use are written nationally, not by the Union.

The public offer to a healthy European adult is small, cheap and mostly conversational. Germany's statutory funds pay for the Gesundheitsuntersuchung, set out in the health examination directive of the Gemeinsamer Bundesausschuss (Federal Joint Committee): once between 18 and 34 as a history, examination and risk assessment, then every three years from 35, when blood glucose, cholesterol and a urine test are added, along with a one-off hepatitis B and C screen and, for men from 65, a single ultrasound for abdominal aortic aneurysm. England's National Health Service (NHS) Health Check gives people aged 40 to 74 who do not already have a qualifying condition a cardiovascular risk assessment every five years, and France's Mon bilan prévention offers four free consultations of 30 to 45 minutes at ages 18 to 25, 45 to 50, 60 to 65 and 70 to 75, delivered by a doctor, nurse, pharmacist or midwife and built around a conversation rather than a test panel.

Where each system stops is a stated decision, not an oversight. The UK National Screening Committee's appraisal criteria, revised in September 2022, demand a simple, safe, precise and validated test plus evidence that intervening before symptoms appear produces better outcomes than usual care; applying them to prostate cancer in March 2026, the committee advised against population screening and backed only targeted two-yearly prostate specific antigen (PSA) testing for men aged 45 to 61 who carry a BRCA2 gene variant alongside a relevant family history. Sweden's Socialstyrelsen (National Board of Health and Welfare) has separately ruled that PSA screening should not be offered to men aged 50 to 70, because a national programme would diagnose many men with cancer that would never have made them ill, and the Netherlands went furthest by legislating: under the Wet op het bevolkingsonderzoek (Population Screening Act), cancer screening, screening using ionising radiation and screening for conditions that cannot be treated each require a ministerial licence granted on the advice of the Gezondheidsraad (Health Council of the Netherlands) and refused where expected benefit does not outweigh risk, and the Dutch national institute for public health and the environment states that offering a magnetic resonance imaging (MRI) or computed tomography (CT) scan as a health test is not permitted there.

None of this makes the tests unobtainable. Imaging for a symptom, coronary assessment for chest pain, colonoscopy after a positive bowel screening test, bone density scanning for fracture risk and genetic testing where family history warrants it are ordinary care in most of these systems, though the gate can be legal as well as clinical: Germany's Gendiagnostikgesetz (Genetic Diagnostics Act) reserves predictive genetic testing to doctors holding the relevant qualification and requires counselling both before the test and after the result. Germany also makes the private layer unusually visible, since services a doctor may sell privately are called Individuelle Gesundheitsleistungen (individual health services, or IGeL) and the statutory funds' own Medizinischer Dienst Bund publishes evidence assessments of them, rating the PSA test for early prostate cancer detection tendenziell negativ, tending to negative.

Clinical responsibility rests with a named doctor on a national register, and those registers are national rather than European. The United Kingdom has the General Medical Council (GMC) and its Specialist Register, France the Conseil national de l'Ordre des médecins, Germany the Landesärztekammern (state medical chambers), and Switzerland the Medizinalberuferegister (MedReg) held by the Bundesamt für Gesundheit (Federal Office of Public Health), on which every practising doctor has had to appear since 1 January 2018. Longevity medicine is a recognised speciality essentially nowhere in the region: it is absent from Annex V of Directive 2005/36/EC on the recognition of professional qualifications, the list member states recognise automatically, and from the German medical association's model training regulation, whereas geriatric medicine is a distinct speciality in more than twenty European countries, so the registrable qualification behind a longevity practice is always something else and a register search will name it.

Prescribing fragments hardest of all: somatropin, recombinant human growth hormone, is authorised in the European Union only for growth hormone deficiency and a short list of growth disorders, which makes any use aimed at ageing off-label, and the off-label rules themselves are not uniform, since British doctors must satisfy the GMC that there is sufficient evidence or experience of safety and efficacy and must own the monitoring, while Italian doctors work under Law 94 of 8 April 1998, which permits off-label use only where an authorised medicine cannot usefully treat the patient and the use rests on published data, after the patient has been informed and has consented. Most injectable peptides sold in this market hold no marketing authorisation anywhere in the region, so supply runs through the pharmacy compounding exemption in Article 3 of Directive 2001/83/EC or a national unlicensed-import scheme, and the United Kingdom's Medicines and Healthcare products Regulatory Agency states that such a special must answer an individual patient's clinical need, not cost or convenience. Cell-based products are stricter again: they are advanced therapy medicinal products (ATMPs) under Regulation (EC) No 1394/2007 and normally need a central marketing authorisation, the Article 28 hospital exemption reaching only non-routine preparation for a single patient, used in a hospital under a doctor's responsibility inside the same member state, and in March 2025 the European Medicines Agency and the Heads of Medicines Agencies warned jointly that unregulated ATMPs marketed direct to patients pose serious risks to health.

The residential format is not an invention of this market. German statutory insurance still pays for treatment at spa towns: sickness funds provide medically necessary outpatient preventive treatment at a recognised Kurort under paragraph 23 of the Fifth Book of the Social Code (SGB V), which the statute words as something the fund provides rather than may provide. The private clinic-hotel sits on that older habit and reprices it, which is why a medical week by a lake or in the mountains reads as a plausible product here and rarely does elsewhere.

Two quoted prices for the same named test usually differ on what surrounds it: a scan reported on site by a consultant radiologist, a panel run in an accredited laboratory, and a price that carries the follow-up consultation, the written plan and the repeat test all cost more than a scanner slot and a printout, and a residential format adds hotel nights, catering and staff hours that are not diagnostics at all. Insurance almost never pays. Directive 2011/24/EU on patients' rights in cross-border healthcare reimburses treatment abroad only where that treatment is among the benefits you are entitled to at home, and only up to what the home system would have paid; the European Health Insurance Card (EHIC) covers neither planned treatment nor private providers; and Switzerland sits outside the directive altogether.

A doctor licensed in one member state is not automatically your doctor in another, and what is lawful to buy also moves with the border, France for instance penalising the ordering of genetic testing outside the medical and research framework its law sets out. Directive 2011/24/EU requires the treating country to have professional liability arrangements and complaints procedures and gives you the right to at least a copy of your medical record, and Commission Implementing Directive 2012/52/EU means a prescription written abroad should carry the details a pharmacy at home needs, but neither obliges your own doctor to continue a regimen they did not start or to act on a report written in another language and another clinical culture. So the questions worth asking before booking are who telephones you about an ambiguous result and how soon, who holds the images and the raw laboratory data and in what format you can take them home, and whether the recommended recheck in three or six months means another flight.